Altasciences supported Metsera, Inc., in advancing its GLP-1 receptor agonist programs for obesity and metabolic diseases, including the successful Phase I/II trial of MET-097i, which demonstrated a 7.5% body weight reduction and a 380-hour half-life. Altasciences provided integrated drug development solutions, enabling Metsera to initiate a 16-week Phase II trial for MET-097i and clinical trials for additional candidates, MET-233i and MET-002.